Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

GB3226, a novel, orally active, first-in-class small molecule inhibitor of ENL-yeats and FLT3 kinase for the treatment of Relapsed/Refractory Acute Myeloid Leukemia

Louis Renzetti, Stacia Kargman, Joseph Vacca, Mayumi Sugita, Sebastien Degorce, Tammy Ladduwahetty, Bradley Sherborne, Simon Taylor, Gillian Watt, Brian Jacoby, Bhupinder Singh, Monica Guzman

Blood (2025) 146 (Supplement 1): 6106.

https://doi.org/10.1182/blood-2025-6106

Published: 2025

Journal Articles

Redefining eIF4E's function in Acute Myeloid Leukemia: Implications for engraftment and survival

Leandro Martinez, Biljana Kraljacic, Kata Alilovic, Winnie Yip, Mayumi Sugita, Gail Roboz, Katherine Borden, Monica Guzman

Blood (2025) 146 (Supplement 1): 3248.

https://doi.org/10.1182/blood-2025-3248

Published: 2025

Journal Articles

Characterization of antecedent clonal hematopoiesis (CH) mutations in lymphoid and plasma cell neoplasms

Pinkal Desai, Zichan Li, Ying Li, Nuria Mencia-Trinchant, Kathryn Gorski, Wodan Ling, Ellen Ritchie, Michael Samuel, Jonathan Canaani, Michal Bar-Natan, Olivier Elemento, Lesley Tinker, Wendy Cozen, Monica Guzman, Andrea Sboner, Gail Roboz

Blood (2025) 146 (Supplement 1): 1399.

https://doi.org/10.1182/blood-2025-1399

Published: 2025

Journal Articles

A compelling case for central pathology review of multiparameter flow cytometry measurable residual disease results in Acute Myeloid Leukemia (AML) clinical trials: Data from the PALG-AML1/2016 multicenter randomized study

Blood (2025) 146 (Supplement 1): 1737.

https://doi.org/10.1182/blood-2025-1737

Published: 2025

Journal Articles

Identifying splice variants of cell surface proteins for chimeric antigen receptor T cell therapy of Acute Myeloid Leukemia

Annamaria Cesarano, Pooja Gangras, Thac Duong, Francesca Albano, Francesco Di Meo, Justin Layer, Brandon Kale, Stephanie Suarez, Manuel Espinoza-Gutarra, Utpal Dave, Andrei Thomas-Tikhonenko, Monica Guzman, Timothy Shaw, Jorge Mansilla-Soto, Ly Vu, Fabiana Perna

Blood (2025) 146 (Supplement 1): 4119.

https://doi.org/10.1182/blood-2025-4119

Published: 2025

Journal Articles

Prospective assessment of measurable residual disease kinetics in intensively treated patients with Acute Myeloid Leukemia (AML) - results of the PALG-AML1/2016 study

Blood (2025) 146 (Supplement 1): 344.

https://doi.org/10.1182/blood-2025-344

Published: 2025

Journal Articles

North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need

Naveen Pemmaraju, Hagop Kantarjian, Kendra Sweet, Eunice Wang, Jayastu Senapati, Nathaniel R. Wilson, Marina Konopleva, Arthur E. Frankel, Vikas Gupta, Ruben Mesa, Matthew Ulrickson, Edward Gorak, Sumeet Bhatia, Tulin Budak-Alpdogan, James Mason, Maria Teresa Garcia-Romero, Norma Lopez-Santiago, Gabriela Cesarman-Maus, Pankit Vachhani, Sangmin Lee, Vijaya Raj Bhatt, William Blum, Roland B. Walter, Dale Bixby, Ivana Gojo, Madeleine Duvic, Raajit K. Rampal, Marcos de Lima, James Foran, Amir T. Fathi, Aric Cameron Hall, Meagan A. Jacoby, Jeffrey Lancet, Gabriel Mannis, Anthony S. Stein, Alice Mims, David Rizzieri, Rebecca Olin, Alexander Perl, Gary Schiller, Paul Shami, Richard M. Stone, Stephen Strickland, Matthew J. Wieduwilt, Naval Daver, Farhad Ravandi, Sumithira Vasu, Monica Guzman, Gail J. Roboz, Joseph Khoury, Muzaffar Qazilbash, Phyu P. Aung, Branko Cuglievan, Yazan Madanat, Mohamed A. Kharfan-Dabaja, Anna Pawlowska, Justin Taylor, Martin Tallman, Prajwal Dhakal, Andrew A. Lane

Blood (2023) 141 (6): 567–578.

https://doi.org/10.1182/blood.2022017865

Published: 2023

Journal Articles

GLI3 repressor determines Hedgehog pathway activation and is required for response to SMO antagonist glasdegib in AML

Parvesh Chaudhry, Mohan Singh, Timothy J. Triche, Monica Guzman, Akil A. Merchant

Blood (2017) 129 (26): 3465–3475.

https://doi.org/10.1182/blood-2016-05-718585

Published: 2017

Includes: Supplemental data

Journal Articles

Evolution of acute myelogenous leukemia stem cell properties after treatment and progression

Tzu-Chieh Ho, Mark LaMere, Brett M. Stevens, John M. Ashton, Jason R. Myers, Kristen M. O’Dwyer, Jane L. Liesveld, Jason H. Mendler, Monica Guzman, Jennifer D. Morrissette, Jianhua Zhao, Eunice S. Wang, Meir Wetzler, Craig T. Jordan, Michael W. Becker

Blood (2016) 128 (13): 1671–1678.

https://doi.org/10.1182/blood-2016-02-695312

Published: 2016

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

GB3226, a novel, orally active, first-in-class small molecule inhibitor of ENL-yeats and FLT3 kinase for the treatment of Relapsed/Refractory Acute Myeloid Leukemia

Redefining eIF4E's function in Acute Myeloid Leukemia: Implications for engraftment and survival

Characterization of antecedent clonal hematopoiesis (CH) mutations in lymphoid and plasma cell neoplasms

A compelling case for central pathology review of multiparameter flow cytometry measurable residual disease results in Acute Myeloid Leukemia (AML) clinical trials: Data from the PALG-AML1/2016 multicenter randomized study

Identifying splice variants of cell surface proteins for chimeric antigen receptor T cell therapy of Acute Myeloid Leukemia

Prospective assessment of measurable residual disease kinetics in intensively treated patients with Acute Myeloid Leukemia (AML) - results of the PALG-AML1/2016 study

North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need

GLI3 repressor determines Hedgehog pathway activation and is required for response to SMO antagonist glasdegib in AML

Evolution of acute myelogenous leukemia stem cell properties after treatment and progression

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only